| Name | Title | Contact Details |
|---|
Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. Uncontrolled, progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye.
Monogram Biosciences, Inc. (Monogram) is a life sciences company committed to advancing personalized medicine and improving patient outcomes through the development of molecular diagnostic products that guide and target the appropriate treatments
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
AVAX Technologies is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Qualicaps is a global supplier of two-piece capsules and related encapsulation equipment. Employees are our most valuable internal asset and we foster a creative, challenging environment in which personal and professional achievements are recognized.